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SF-36Abstract The main objective of this study was to identify the risk factors of dyslipi-
demia andmeasure its impact on patients’ quality of life (QOL). Secondary objectives
were to determine the percentage of dyslipidemia and assess the predictive factors
affecting patients’ QOL. A cross-sectional study was conducted in a sample of Leba-
nese population. A standardized questionnaire was developed to assess the QOL using
the Short form-36 (SF-36) score. A total of 452 individuals were interviewed, of which
59.5% were females. The mean age was 43.3 ± 15.6 years, and 24.8% had dyslipi-
demia. The results show a lower overall QOL score among dyslipidemic patients com-
pared with controls (57.9% and 76.5%, respectively; p < 0.001). Waterpipe smoking
[adjusted odds ratio (ORa) = 4.113, 95% confidence interval (CI): 1.696–9.971,
p = 0.002], hypertension (ORa = 3.597, 95% CI: 1.818–7.116, p < 0.001), diabetes
(ORa = 3.441, 95% CI: 1.587–7.462, p = 0.002), cigarette smoking (ORa = 2.966, 95%
CI: 1.516–5.804, p = 0.001), and passive smoking (ORa = 2.716, 95% CI: 1.376–
5.358, p = 0.004) were significantly associated with dyslipidemia in individuals older
than 30 years. A higher overall QOL score (p = 0.013) was observed in patients treated
with statins in comparison with other lipid-lowering medications. In addition to clin-
ical and economical consequences, dyslipidemia may have a significant impact on
patients’ QOL. Further research is needed to confirm the impact of treatment on dys-
lipidemic patients’ QOL in order to maximize the overall benefits of therapy.
 2016 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).c Hariri
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According to the recommendations of the European
Society of Cardiology in 2011, dyslipidemia is
defined as abnormal levels of lipids in the blood
(cholesterol, triglycerides, phospholipids, and free
fatty acids) [1]. The sixth edition of the survey
ObEpi Roche [2], conducted in France between
January and March 2012, in a sample of more
than 25,000 individuals aged 18 years and over,
has shown 15.9% of the French population to be
treated for dyslipidemia. In the United States,
49% of adults have a total cholesterol level of
P200 mg/dL [3].
Dyslipidemia is considered a major risk factor
for cardiovascular complications [4]. Many studies
such as those conducted by the World Health Orga-
nization and ‘‘Framingham” created the associa-
tion of plasma cholesterol level with the risk of
cardiovascular disease [5,6]. This association is
also confirmed in the results of a meta-analysis of
10 cohort studies, which stated that for a reduction
of 0.6 mmol/L of serum total cholesterol in adults
aged over 60 years, the risk of fatal cardiovascular
disease decreases by 27% [7]. Risk factors for dys-
lipidemia are well documented, including lifestyle
choices such as high-fat diet, smoking, alcohol con-
sumption, physical inactivity, metabolic disorders
such as obesity and diabetes, family history, and
genetic differences [8–11].
Moreover, it was demonstrated that dyslipi-
demia may have an impact on the quality of life
(QOL) of patients [12,13]. The World Health Orga-
nization defines QOL as ‘‘an individual’s perception
of their position in life in the context of culture and
value systems in which they live and in relation to
their goals, expectations, standards and concerns.”
This definition implies that the concept of QOL is
subjective and multidimensional, including positive
and negative elements [14]. In 2001, Lalonde et al.
[15] have shown that patients with dyslipidemia
had low QOL. This may be due to rigid dietary pre-
scriptions, medication side effects, the need for
regular medical care [15], and psychological
effect.
Improvement of QOL would be very important in
the management of patients with dyslipidemia.
The increasing trend in the numbers of patients
with dyslipidemia makes this evaluation highly rel-
evant, in order to better manage dyslipidemic
patients and consequently improve their QOL
[16]. However, a few studies have investigated
the impact of detection and treatment of dyslipi-
demia on QOL. Identification of clinical variables
that reduce QOL should help in adopting healthcaremeasures with greatest impact on target popula-
tions [13]. The impact of dyslipidemia on the QOL
of Lebanese patients has never been studied until
now.
Therefore, a pilot study was conducted in this
context. Its main objective was to identify dyslipi-
demia risk factors and measure the impact of this
disease on patients’ QOL. Secondary objectives
were to determine the percentage of dyslipidemia
and assess the predictive factors affecting QOL.
2. Materials and methods
2.1. Study design and population
This is an observational cross-sectional study, con-
ducted in all districts of Lebanon. Our sample was
constructed from community pharmacies. One per-
cent (26 pharmacies) of total Lebanese pharmacies
was included in our study. These 26 pharmacies
were randomly chosen from the list of pharmacies
in Lebanon, obtained from the Order of Lebanese
Pharmacists.
Lebanese people of both genders, aged 18 years
and above, were included. Individuals having a
temporary illness (such as cold); those suffering
from cancer, and neurological and psychological
diseases; and pregnant women were excluded.
Since there are no published data on the preva-
lence of dyslipidemia in Lebanon, sample size was
not previously calculated.
2.2. Data collection
Data were collected using a structured question-
naire. Questionnaires were delivered to the
included pharmacies. In each pharmacy, the first
five patients, who agreed to participate, were
selected. Oral consent was obtained from each
patient. A self-administered questionnaire was
completed by the participants themselves. Privacy
and anonymity were respected.
The survey was conducted between March and
June 2014, using a standardized Arabic question-
naire containing 98 questions most of which were
closed.
2.2.1. Questionnaire
The questionnaire was divided into five parts:
sociodemographic, life style, diseases, medica-
tions, and QOL. The first two parts of the question-
naire were developed from general questions and
previously documented risk factors [8–11]. It
extracted information regarding sex, age, district,
employment, active and passive smoking, physical
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tory, and medications taken at home.
2.3. QOL measurement
An Arabic validated version of the Short form-36
(SF-36) was used as described by Sabbah et al.
[17]. QOL was assessed by the SF-36, a short form
of the Medical Outcome Study [18]. It contains 36
questions. The SF-36 assesses eight health dimen-
sions: physical functioning, role physical limita-
tion, bodily pain (BP), general health, social
functioning, role emotional limitation, mental
health, and vitality. From these eight scales, it is
possible to calculate two summary scores, physical
component summary (PCS) (physical functioning,
role physical limitation, bodily pain and general
health) and mental component summary (MCS)
(social functioning, role emotional limitation, men-
tal health and vitality), and also the overall QOL.
Dimensions, summary scores, and the overall
QOL are presented in percentages, which vary from
0% to 100%. Higher scores represent better QOL,
indicating higher levels of functioning or well-being.
2.4. Statistical analysis
Questionnaire data were collected and processed
by Statistical Package for the Social Sciences, Ver-
sion 22. Categorical variables were presented in
frequencies and percentages, and continuous vari-
ables as means with standard deviations.
Then the participants were classified into two
groups. Individuals diagnosed with dyslipidemia by
a physician were considered as cases. Controls
were those who did not suffer from dyslipidemia.
A bivariate statistical analysis was conducted
using chi-square, Fisher exact, t test, and analysis
of variance.
In addition, two multivariate regressions were
conducted to eliminate confounders. Logistic
regression (backward logistic regression) was per-
formed to identify the risk factors of dyslipidemia.
The dependent variable was dyslipidemia, and vari-
ables giving a p value of <0.2 in the bivariate anal-
ysis were independent variables. The Hosmer and
Lemeshow test was not significant (p = 0.681), indi-
cating that this logistic regression can be used, and
the model is adequate to the data. The value of
Nagelkerke R2 (0.595) suggest that 64.9% of the
achievement by dyslipidemia were explained by
the independent variables introduced.
Similarly, a linear regression was performed to
determine predictive factors affecting the QOL.
The dependent variables were QOL, PCS, MCS,and all variables giving a p value of <0.2 in the
bivariate analysis as independent variables. Condi-
tions of normality, linearity, and homoscedasticity
were checked for the linear regressions.
Finally, a subgroup analysis was also performed.
An association was considered significant for
p < 0.05.
3. Results
The questionnaire was administered to 581 individ-
uals. The response rate was 78% (454 participants).
Among the 452 individuals included, 269 were
females (59.5%). The age of the population ranged
from 18 years to 84 years, with a mean value of
43.3 ± 15.6 years. Approximately one-quarter of
the sample (24.8%) was treated for dyslipidemia
and diagnosed for more than 3 months.
3.1. Variables associated with dyslipidemia
Association of sociodemographic and life style vari-
ables with dyslipidemia was investigated using a
bivariate analysis (Table 1). Among dyslipidemic
patients, males (p = 0.032), patients with a body
mass index (BMI) of >30 kg/m2 (p < 0.01), active
and passive smokers (p < 0.01), and alcohol con-
sumers (p < 0.01) had significantly higher percent-
ages. Among the control individuals, significantly
higher percentages were seen in those practicing
sports and fasting (p < 0.01).
3.2. Quality of life
The bivariate analysis showed that the eight
dimensions, their two component summaries (PCS
and MCS), and the overall QOL score were signifi-
cantly lower among patients with dyslipidemia
(p < 0.001) than among nondyslipidemic individuals
(Figure 1).
3.3. Multivariate analysis
3.3.1. Logistic regression
A logistic regression to identify risk factors of dys-
lipidemia was performed on individuals older than
30 years (73.2% of participants), including 110
cases and 221 controls.
In the last step of the regression (backward
logistic regression), the variables remained signifi-
cantly associated with dyslipidemia, as presented
in Table 2.
Variables such as stimulant or alcohol consump-
tion, sport practice, and sex were not significantly
associated with dyslipidemia.
Table 1 Variables in dyslipidemic (case) and nondyslipidemic (control) participants.
Case, n (%) Control, n (%) p
Sex 0.032
Male 55 (30.1) 128 (69.9)
Female 57 (21.2) 212 (78.8)
BMI <0.001
Underweight 0 (0) 10 (100)
Normal 20 (8.6) 213 (91.4)
Overweight 58 (37.9) 95 (62.1)
Obesity 34 (60.7) 22 (39.3)
District 0.094
Beirut 18 (22.8) 61 (77.2)
Mont Lebanon 19 (25) 57 (75)
Bekaa 20 (26.7) 55 (73.3)
North Lebanon 18 (25.4) 53 (74.6)
Nabatieh 20 (25.6) 58 (74.4)
South Lebanon 17 (23.3) 56 (76.7)
Income 0.081
<675,000 LP 56 (31.1) 124 (68.9)
675,000–,000,000 LP 16 (20.5) 62 (79.5)
1,000,000–2,000,000 LP 24 (19.4) 100 (80.6)
>2,000,000 LP 16 (22.9) 54 (77.1)
Cigarette smoking <0.001
Yes 62 (47.7) 68 (52.3)
No 50 (36.3) 272 (63.7)
Waterpipe smoking 0.065
Yes 19 (28.4) 48 (71.6)
No 93 (28.7) 292 (71.3)
Passive smoking <0.001
Yes 76 (34.2) 146 (65.8)
No 36 (15.7) 194 (84.3)
Sport <0.001
Yes 24 (13) 160 (87)
No 88 (32.8) 180 (67.2)
Omega 0.183
Yes 20 (33.3) 40 (66.7)
No 92 (20.8) 300 (79.2)
Fasting <0.001
Yes 84 (21.4) 314 (78.6)
No 28 (51.9) 26 (48.1)
Alcohol <0.001
Yes 17 (58.6) 12 (41.4)
No 95 (16.9) 328 (83.1)
BMI = body mass index.
p-value in bold i < 0.05 is statistical significant.
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waterpipe smoking [adjusted odds ratio (ORa)
= 4.113, 95% CI: 1.696–9.971, p = 0.002], hyperten-
sion (ORa = 3.597, 95% CI: 1.818–7.116, p < 0.001),
diabetes (ORa = 3.441, 95% CI: 1.587–7.462,
p = 0.002), cigarette smoking (ORa = 2.966, 95%
CI: 1.516–5.804, p = 0.001), and passive smoking
(ORa = 2.716, 95% CI: 1.376–5.358, p = 0.004) were
significantly associated with dyslipidemia.3.3.2. Linear regression
Results of the linear regression (Table 3) showed
that factors such as sports (p < 0.001), high salary
(>2 million LP, compared with a salary of
<2,000,000 LP; p = 0.013), taking omega
(p = 0.004), and dwelling in Bekaa (p < 0.001) and
Mount Lebanon (in comparison with Beirut;
p = 0.009) increased the PCS. However, dyslipi-
demia (p = 0.001), passive smoking (p < 0.001),
010
20
30
40
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80
90
PF RP BP GH VT SF RE MH PCS MCS QDV
Control 89.5 84.1 82.1 61.1 62.1 82.4 80.8 69.7 79.2 73.7 76.5
Case 60.2 50.7 65 45.8 47.4 66.7 66.1 61.7 55.4 60.5 57.9
Figure 1 Mean scores of the eight dimensions, physical and mental component summaries, and the overall score of
quality of life of the SF-36, comparing dyslipidemia and control groups. BP = bodily pain; GH = general health;
MCS = mental component summary; MH = mental health; PCS = physical component summary; PF = physical function-
ing; RE = role emotional limitation; RP = role physical limitation; SF = social functioning; VT = vitality.
Table 2 Dyslipidemia risk factors in adults aged over 30 years.
Risk factors p ORa CI (95%)
Passive smoking 0.004 2.716 1.376–5.358
Monitoring fat <0.001 0.319 0.199–0.513
Cigarette smoking 0.001 2.966 1.516–5.804
Waterpipe smoking 0.002 4.113 1.696–9.971
Hypertension <0.001 3.597 1.818–7.116
Diabetes 0.002 3.441 1.587–7.462
BMI class (2) <0.001 0.056 0.020–0.161
BMI class (3) 0.007 0.281 0.112–0.704
BMI class (2) = 18.5–24.99 kg/m2 and BMI class (3) = 25–29.99 kg/m2 compared with BMI > 30 kg/m2.
BMI = body mass index; CI = confidence interval; ORa = adjusted odds ratio.
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the PCS. Variables such as cigarette and waterpipe
smoking, alcohol and stimulant consumption, sex,
and BMI were not significantly associated with the
PCS.
In addition, sports (p < 0.001) or dwelling in
Bekaa (in comparison with Beirut; p = 0.029) affect
the MCS positively. However, passive smoking
(p < 0.001), unemployment (p < 0.001), and being
overweight or obese (BMI > 25 kg/m2 compared
with BMI < 25 kg/m2; p = 0.013) affect the MCS neg-
atively. Variables such as cigarette and waterpipe
smoking, alcohol and stimulant consumption, sex,
income, fasting, taking omega, and dyslipidemia
were not significantly associated with the MCS.
The QOL score is increased by sports (p < 0.01)
and dwelling in Bekaa (in comparison with Beirut)
(p = 0.002), and decreased by unemployment
(p < 0.001), being overweight or obese
(BMI > 25 kg/m2 compared with BMI < 25 kg/m2;p = 0.004), cigarette smoking (p = 0.038), as well
as passive smoking (p < 0.001). Confounders were
waterpipe smoking, alcohol and stimulant
consumption, sex, income, fasting, taking omega,
and dyslipidemia.
3.4. Subgroup analysis
3.4.1. Subgroup of dyslipidemic patients
(cases)
Table 4 shows higher QOL scores in dyslipidemic
patients treated with statins compared with those
treated with other antidyslipidemic medications.
This difference was found to be statistically signif-
icant, especially for the PCS (p = 0.005) and the
total QOL (p = 0.013).
In contrast, this difference was not significant
with respect to the number of medications, treat-
ment compliance, and regular visits to the
physician.
Table 3 Predictors of PCS, MCS, and QOL.
Dependent variable Predictors Unstand. b Stand. b CI (95%) p
PCS Age 0.617 ± 0.054 0.453 0.723; 0.510 <0.001
Sport 6.456 ± 1.492 0.149 3.524; 9.387 <0.001
Unemployment 5.985 ± 1.541 0.133 9.013; 2.956 <0.001
Passive smoking 5.712 ± 1.401 0.134 8.464; 2.959 <0.001
Bekaa/Beyrouth 7.934 ± 1.873 0.138 4.253; 11.614 <0.001
Dyslipidemia 6.495 ± 1.910 0.132 10.248; 2.741 0.001
Omega 4.912 ± 1.677 0.094 1.616; 8.209 0.004
Fasting 6.295 ± 2.218 0.096 10.655; 1.936 0.005
ML/Beirut 4.934 ± 1.869 0.086 1.261; 8.606 0.009
Salary > 2,000,000 5.012 ± 2.012 0.085 1.057; 8.966 0.013
MCS Age 0.203 ± 0.061 0.155 0.323; 0.084 0.001
Passive smoking 9.105 ± 1.7 0.221 12.477; 5.764 <0.001
Unemployment 9.049 ± 1.825 0.208 12.637; 5.462 <0.001
Sport 8.069 ± 1.804 0.193 4.524; 11.613 <0.001
BMI > 25 4.609 ± 1.841 0.112 8.227; 0.992 0.013
Bekaa/Beirut 4.917 ± 2.251 0.089 0.493; 9.340 0.029
QOL Age 0.394 ± 0.055 0.316 0.502; 0.286 <0.001
Sport 7.337 ± 1.537 0.184 4.317; 10.357 <0.001
Passive smoking 7.430 ± 1.437 0.190 10.255; 4.605 <0.001
Unemployment 8.453 ± 1.522 0.205 11.444; 5.462 <0.001
Bekaa/Beirut 5.843 ± 1.887 0.111 2.134; 9.551 0.002
BMI > 25 4.458 ± 1.537 0.114 7.479; 1.437 0.004
Cigarette 3.648 ± 1.752 0.088 7.091; 0.204 0.038
BMI = body mass index; CI = confidence interval; MCS = mental component summary; ML = Mount Lebanon; PCS = physical compo-
nent summary; QOL = quality of life; Stand. = standardized; Unstand. = unstandardized.
Table 4 Comparison of scores in the subgroup of cases.
PCS MCS QOL
% p % p % p
Taking a statin
Yes 57.6 ± 21.2 0.005 61.9 ± 22.3 0.074 59.7 ± 20.3 0.013
No 40.2 ± 18.9 50.7 ± 16.6 45.5 ± 15.4
Number of drugs for dyslipidemia
1 55.7 ± 21.7 0.739 61.4 ± 21.5 0.254 58.5 ± 20.0 0.797
2 53.6 ± 21.4 54.2 ± 25.1 53.9 ± 22.6
Compliance with dyslipidemia treatment
Yes 55.5 ± 21.6 0.905 61.3 ± 21.8 0.286 58.4 ± 20.1 0.522
No 54.8 ± 22.4 54.6 ± 22.8 54.7 ± 21.9
Visiting doctor regularly
Yes 55.4 ± 21.9 0.979 60 ± 22.3 0.568 57.7 ± 20.7 0.747
No 55.5 ± 20.6 63.4 ± 20.2 59.5 ± 18.5
MCS = mental component summary; PCS = physical component summary; QOL = quality of life.
p-value in bold i < 0.05 is statistical significant.
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diseases
Figure 2 shows that among patients with chronic
diseases, a significant difference exists only in
the MCS between dyslipidemic patients (60.5 ± 22)
and those with other chronic disease(s) (58
± 25.2; p = 0.039).4. Discussion
The objectives of this study were to determine
the risk factors of dyslipidemia and its percent-
age, measure QOL and analyze their predictive
factors among a sample of the Lebanese
population.
PCS MCS QOL
Dyslipidemic paents 55.4 60.5 57.9
Other chronic disease(s) 60.1 58 59.1
48
50
52
54
56
58
60
62
64
p = 0.162 p = 0.039 p = 0.719
Dyslipidemic paents Other chronic disease(s)
Figure 2 Comparison of scores in the subgroup of patients with chronic diseases. MCS = mental component summary;
PCS = physical component summary; QOL = quality of life.
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demia had significantly lower QOL than individuals
without dyslipidemia (p < 0.001). This finding is
consistent with a Canadian study conducted in hos-
pitals [15], where patients (reporting high levels of
blood lipids, as confirmed by a physician, and
receiving treatment for dyslipidemia) had lower
scores of QOL (measured by the SF-36) than the
control group.
Indeed, few studies have evaluated the impact
of dyslipidemia on QOL. Most studies assess the
impact of chronic diseases in general [19], cardio-
vascular disease [13,15] and especially hyperten-
sion [16,20–23], on the QOL of patients. Chronic
diseases [24] affect QOL and physical, emotional,
and social well-being of patients. Therefore, mea-
suring QOL is considered an important factor in
assessing the health of individuals.
Results of the linear regression showed that age,
passive smoking, smoking cigarettes, a BMI of
>25 kg/m2, and not having an occupation affect
QOL negatively, while sports improve QOL. The
same results were shown in previous studies with
respect to overweight and obesity [13,20,25–27],
smoking [20,28], unemployment [29], and sports
[13,30].
The percentage of dyslipidemic patients in this
study was 24.8%. A study conducted in ‘‘Hoˆtel-
Dieu de France” hospital [30] in 1999 to determine
the lipid profile of the Lebanese population has
reported percentages of individuals with signifi-
cantly high blood lipids than recommended: 19%
for total cholesterol and 27% for low-density
lipoprotein.Results of the logistic regression reported that
smoking waterpipe is the most important risk fac-
tor of dyslipidemia. Waterpipe smokers were four
times more at risk to develop dyslipidemia than
non-waterpipe smokers. Similarly, hypertension
and diabetes increase the risk of being dyslipidemic
by 3.5 times. Active and passive cigarette smokers
were 2.9 and 2.7 times more likely to develop dys-
lipidemia, respectively. By contrast, having a nor-
mal BMI or being overweight decreases the risk
compared with obese individuals. Monitoring of
dietary fat is also considered a protective factor.
Our results are concordant with those of other
studies that identified diabetes [31–35], hyperten-
sion [31,32,34–36], cigarette smoking [31,35,36],
and higher BMI [32–36] as risk factors for dyslipi-
demia. Diet was identified as a protective factor
[31].
This study had some limitations. The partici-
pants themselves completed the questionnaires,
so the results of the survey are based on self-
reported data. Among the questions, respondents
were asked to evaluate themselves with two obsta-
cles: difficulty of self-assessment and possibility of
cheating. Therefore, information bias cannot be
absent. QOL is directly related to subjective health
status of patients, functions of daily life, and dis-
ease severity [37]. The degree of consensus
between the desired and real-life situations is the
QOL [38].
However, this study was randomly conducted in
all regions of Lebanon, which could minimize selec-
tion bias. One of the strong points of this study is
the use of SF-36, which is the best choice, in
322 A. Farhat et al.comparison with the short-form 8 and 12 question-
naires SF-8 and SF-12 (items obtained from the SF-
36), although it is lengthier. The SF-36 is the origi-
nal version. It is a widely used tool to measure the
QOL of patients in different populations, including
aspects such as function, dysfunction, and emo-
tional and physical well-being [28].
A high acceptance rate (78%) could be a strong
point for this study. Good cooperation of the par-
ticipants was noted, except for those who refused
to participate in the survey due to either a lack
of time or a lack of confidence, or for the fear of
disclosing information, which they described as
too personal. In addition, questionnaires filled by
those who agreed to participate had very few
‘‘missing values.”
Being conducted for the first time in Lebanon,
this study was a preamble to organize larger studies
in the future in order to confirm the impact of treat-
ment on dyslipidemic patients’ QOL, and eventually
to maximize the overall benefits of therapy.
5. Conclusion
The eight dimensions, their two components sum-
maries (PCS and MCS), and the overall QOL score
were significantly lower among patients with dys-
lipidemia (p < 0.001) than among nondyslipidemic
individuals.
The results of our study show that active and
passive smoking (waterpipe and cigarette) and suf-
fering from hypertension or diabetes are risk fac-
tors for dyslipidemia. Avoiding exposure to these
risk factors can prevent the development of dys-
lipidemia. On the contrary, having a normal BMI
or being overweight, compared with obese individ-
uals, as well as monitoring of dietary fat are con-
sidered protective factors.
This study allowed us to make some suggestions
on factors negatively affecting QOL, such as active
and passive smoking, a BMI of >25 kg/m2, and unem-
ployment, but sports were shown to improve QOL.
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